445303-14-0

Usage

Uses

Used in Synthetic Chemistry:
4-Fluoro-3-(trifluoromethyl)phenylboronic acid pinacol ester is used as a reagent for the synthesis of complex structures or molecular scaffolds. Its reactivity allows for the creation of intricate molecular designs that are essential in advanced chemical research and development.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-Fluoro-3-(trifluoromethyl)phenylboronic acid pinacol ester is used as a precursor in the preparation of drug candidates. Its unique structure and reactivity enable the development of new compounds with potential therapeutic applications.
Used in Suzuki-Miyaura Coupling Reaction:
4-Fluoro-3-(trifluoromethyl)phenylboronic acid pinacol ester is employed as a key reagent in the Suzuki-Miyaura coupling reaction, a widely used method for the formation of carbon-carbon bonds in organic synthesis. This reaction is crucial for the synthesis of a variety of organic compounds, including those with potential applications in materials science and medicinal chemistry.

Upstream product

• 61676-62-8 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 393-37-3 5-bromo-2-fluorobenzotrifluoride 
• 73183-34-3 bis(pinacol)diborane 
• 392-85-8 1-fluoro-2-trifluoromethylbenzene 

Relevant academic research and scientific papers

Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors

Pim kinases are promising therapeutic targets for the treatment of hematological cancers. A potent Pim kinase inhibitor 7f, derived from meridianin C, was further optimized by the replacement of 2-aminopyrimidine with substituted benzene. The optimization of the C-3 and C-5 positions of indole yielded compound 43 with improved cellular potency and high selectivity against a panel of 14 different kinases.

C(sp2)-H Borylation of Fluorinated Arenes Using an Air-Stable Cobalt Precatalyst: Electronically Enhanced Site Selectivity Enables Synthetic Opportunities

Cobalt catalysts with electronically enhanced site selectivity have been developed, as evidenced by the high ortho-to-fluorine selectivity observed in the C(sp2)-H borylation of fluorinated arenes. Both the air-sensitive cobalt(III) dihydride boryl 4-Me-(iPrPNP)Co(H)2BPin (1) and the air-stable cobalt(II) bis(pivalate) 4-Me-(iPrPNP)Co(O2CtBu)2 (2) compounds were effective and exhibited broad functional group tolerance across a wide range of fluoroarenes containing electronically diverse functional groups, regardless of the substitution pattern on the arene. The electronically enhanced ortho-to-fluorine selectivity observed with the cobalt catalysts was maintained in the presence of a benzylic dimethylamine and hydrosilanes, overriding the established directing-group effects observed with precious-metal catalysts. The synthetically useful selectivity observed with cobalt was applied to an efficient synthesis of the anti-inflammatory drug flurbiprofen.

Fluorine-controlled C-H borylation of arenes catalyzed by a PSiN-pincer platinum complex

An efficient, regioselective synthesis of fluorine-substituted arylboronic esters was achieved through fluorine-controlled C-H borylation of arenes with diboron catalyzed by a PSiN-platinum complex. The promising utility of the PSiN-platinum catalyst and its unique regioselectivity were demonstrated for the first time, which would complement the well-developed Ir-catalyzed C-H borylation.

2-PHENYL-6-AZOLYLPYRIDINE-BASED LIGAND AND GROUP VIII TRANSITION METAL COMPLEX

A 2-phenyl-6-azolylpyridine-based ligand is represented by the following formula (I): wherein, X represents nitrogen or C—R10; R1, R2, R3, R4, R5, R6, R7, R8 /su

Substituted imidazol-pyridazine derivatives

The present invention relates to compounds of formula wherein A is an unsubstituted or substituted cyclic group; and R is hydrogen or lower alkyl; or a pharmaceutically acceptable acid addition salt thereof. These compounds are NMDA NR-2B receptor subtype specific blockers and are useful in the treatment of neurodegeneration, depression and pain.

Imidazole derivatives

Novel imidazole derivatives are disclosed. These compounds have a good affinity to the NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers, which have a key function in modulating neuronal activity and plasticity which makes them key players in mediating processes underlying development of CNS as well as learning and memory formation. These compounds are useful in the control or treatment of diseases mediated by this receptor.